Lederman Michael M, Cannon Paula M, Currier Judith S, June Carl H, Kiem Hans Peter, Kuritzkes Daniel R, Lewin Sharon R, Margolis David M, McCune Joseph M, Mellors John W, Schacker Timothy W, Sekaly Rafick P, Tebas Pablo, Walker Bruce D, Douek Daniel C
Case Western Reserve University School of Medicine, Cleveland, OH.
University of Southern California, Los Angeles, CA.
Pathog Immun. 2016 Spring;1(1):154-164. doi: 10.20411/pai.v1i1.133.
With the advent and stunning success of combination antiretroviral therapy (ART) to prolong and improve quality of life for persons with HIV infection, HIV research has been afforded the opportunity to pivot towards studies aimed at finding "a cure." The mere idea that cure of HIV might be possible has energized researchers and the community towards achieving this goal. Funding agencies, both governmental and private, have targeted HIV cure as a high priority; many in the field have responded to these initiatives and the cure research agenda is robust. In this "salon" two editors of , Michael Lederman and Daniel Douek ask whether curing HIV is a realistic, scalable objective. We start with an overview perspective and have asked a number of prominent HIV researchers to add to the discussion.
随着联合抗逆转录病毒疗法（ART）的出现并取得惊人成功，从而延长了HIV感染者的生命并提高了其生活质量，HIV研究有机会转向旨在寻找“治愈方法”的研究。仅仅是HIV有可能被治愈这一想法，就激励着研究人员和整个社会朝着实现这一目标努力。政府和私人的资助机构都将治愈HIV作为高度优先事项；该领域的许多人都对这些举措做出了回应，治愈研究议程进展顺利。在这个“沙龙”中，《》的两位编辑迈克尔·莱德曼（Michael Lederman）和丹尼尔·杜克（Daniel Douek）探讨了治愈HIV是否是一个现实且可扩展的目标。我们首先从一个概述的角度出发，并邀请了一些杰出的HIV研究人员参与讨论。
